avibactam and Hematologic-Neoplasms

avibactam has been researched along with Hematologic-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for avibactam and Hematologic-Neoplasms

Article	Year
Ceftolozane/Tazobactam and Ceftazidime/Avibactam: An Italian Multi-center Retrospective Analysis of Safety and Efficacy in Children With Hematologic Malignancies and Multi-drug Resistant Gram-negative Bacteria Infections. The Pediatric infectious disease journal, 2022, 12-01, Volume: 41, Issue:12 Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Child; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Hematologic Neoplasms; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam	2022
Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2017, Volume: 59 The primary objective was to describe clinical features, treatment and outcomes in patients with carbapenemase-producing Enterobacteriaceae (CPE) bacteremia. Additionally, patients treated with ceftazidime/avibactam (study group) were compared to the rest of the patients (comparator group) to determine the influence of the treatment in both crude mortality and clinical cure.. Multicenter and retrospective study that included patients with hematologic malignancies who had CPE bacteremia. A bivariate analysis was performed to compare the clinical variables between the study group and the control group.. 31 patients were included. Bacteremia was considered primary in 14 (45%) patients. Overall crude mortality at 30days was 45.2% (n=14). Mortality was more frequent when septic shock (78.6% vs 11.8%; p>0.001) and higher Pitt score (6+14 vs 1.5+4; p<0.01) were present. 8 patients (25.8%) received treatment with ceftazidime/avibactam. No significant differences in crude mortality were found between study and comparator groups (p=0.19). In contrast, patients in study group had higher clinical cure rates than the comparator group within 14days of initiating treatment (85.7% vs. 34.8%, respectively, p=0.031).. CPE bacteremia is associated with high mortality in patients with hematologic malignancies. Ceftazidime/avibactam may be an effective alternative for treating these patients. Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacteremia; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cohort Studies; Drug Therapy, Combination; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Hematologic Neoplasms; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Treatment Outcome	2017

Article

Year

Ceftolozane/Tazobactam and Ceftazidime/Avibactam: An Italian Multi-center Retrospective Analysis of Safety and Efficacy in Children With Hematologic Malignancies and Multi-drug Resistant Gram-negative Bacteria Infections.

The Pediatric infectious disease journal, 2022, 12-01, Volume: 41, Issue:12

Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Child; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Hematologic Neoplasms; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam

2022

Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2017, Volume: 59

The primary objective was to describe clinical features, treatment and outcomes in patients with carbapenemase-producing Enterobacteriaceae (CPE) bacteremia. Additionally, patients treated with ceftazidime/avibactam (study group) were compared to the rest of the patients (comparator group) to determine the influence of the treatment in both crude mortality and clinical cure.. Multicenter and retrospective study that included patients with hematologic malignancies who had CPE bacteremia. A bivariate analysis was performed to compare the clinical variables between the study group and the control group.. 31 patients were included. Bacteremia was considered primary in 14 (45%) patients. Overall crude mortality at 30days was 45.2% (n=14). Mortality was more frequent when septic shock (78.6% vs 11.8%; p>0.001) and higher Pitt score (6+14 vs 1.5+4; p<0.01) were present. 8 patients (25.8%) received treatment with ceftazidime/avibactam. No significant differences in crude mortality were found between study and comparator groups (p=0.19). In contrast, patients in study group had higher clinical cure rates than the comparator group within 14days of initiating treatment (85.7% vs. 34.8%, respectively, p=0.031).. CPE bacteremia is associated with high mortality in patients with hematologic malignancies. Ceftazidime/avibactam may be an effective alternative for treating these patients.

Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacteremia; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cohort Studies; Drug Therapy, Combination; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Hematologic Neoplasms; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Treatment Outcome

2017